NEW YORK (GenomeWeb) – OncoCyte said after the close of the market Monday that its net loss in Q4 2016 was down about 9 percent compared to Q4 2015.

The liquid biopsy firm's net loss for the three months ended Dec. 31, 2016 was $3.1 million, or $0.11 per share, compared to a loss of $3.5 million, or $0.14 per share during the prior year's quarter. The company did not report any revenues in the quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.